medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-6-110-116medsovet-1895Research ArticleОнкоурологияOncourologyВОЗМОЖНОСТИ ОПТИЧЕСКОЙ ДИАГНОСТИКИ МЫШЕЧНО-НЕИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯPOSSIBILITIES FOR OPTICAL DIAGNOSIS OF MUSCULAR-NONINVASIVE BLADDER CANCERТРУШИНА. А.TRUSHINA. A.ФИЛОНЕНКОЕ. В.FILONENKOE. V.

д.м.н., профессор

MD, Prof.

РУСАКОВИ. Г.RUSAKOVI. G.

д.м.н., профессор

MD, Prof.

Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал Национального медицинского исследовательского радиологического центра Минздрава РоссииРоссияHerzen Moscow Scientific Research Oncologic Institute - Affiliate of the National Medical Research Radiology Centre of the Ministry of Health of RussiaRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова Минздрава РоссииРоссияSechenov First Moscow State University of the Ministry of Health of RussiaRussian Federation20172006201706110116Copyright © ТРУШИН А.А., ФИЛОНЕНКО Е.В., РУСАКОВ И.Г., 20172017ТРУШИН А.А., ФИЛОНЕНКО Е.В., РУСАКОВ И.Г.TRUSHIN A.A., FILONENKO E.V., RUSAKOV I.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1895

В статье представлен критический обзор методов оптической диагностики мышечно-неинвазивного рака мочевого пузыря (РМП), описаны доступные на данный момент технологии, отмечены их преимущества и недостатки, дан обзор работ по оценке их эффективности, как клинической, так и экономической. За основу взяты результаты работы ведущих научных обществ, таких как European Association of Urology (EAU), the European Organization for Research and Treatment of Cancer (EORTC), Clinical Research Office of the Endourological Society (CROES) и др.

This article provides a critical overview of the methods of optical diagnosis of muscular and non-invasive bladder cancer (BC), describes the technologies available so far, their advantages and disadvantages, and reviews the assessment of their effectiveness, both clinical and economic. The results are based on the work of leading scientific societies, such as the European Association of Urology (EAU), the European Organization for Research and Treatment of cancer (EORTC), Сlinical Research Office of the Endourological Society (Croes), etc.

мочевой пузырьмышечно-неинвазивный ракоптическая диагностикаurinary bladdermuscular noninvasive canceroptical diagnostics.ReferencesInternational Agency for Research on Cancer. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http: //globocan.iarc.fr (Feb. 2, 2014).International Agency for Research on Cancer. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http: //globocan.iarc.fr (Feb. 2, 2014).Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65: 87-108.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65: 87-108.Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006, 49: 466-465.Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006, 49: 466-465.Rink M, Babjuk M, Catto JW et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol, 2013, 64: 624-638.Rink M, Babjuk M, Catto JW et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol, 2013, 64: 624-638.Morgan TM, Keegan KA, Clark PE. Bladder cancer. Curr Opin Oncol, 2011, 23: 275-282.Morgan TM, Keegan KA, Clark PE. Bladder cancer. Curr Opin Oncol, 2011, 23: 275-282.Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol, 2009, 27: 295-300.Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol, 2009, 27: 295-300.Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol, 2009, 182: 2195-2203.Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol, 2009, 182: 2195-2203.Lee JY, Cho KS, Kang DH, et al. A network metaanalysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer, 2015, 15: 566.Lee JY, Cho KS, Kang DH, et al. A network metaanalysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging. BMC Cancer, 2015, 15: 566.Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int, 2011, 108: 1703-1707.Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int, 2011, 108: 1703-1707.Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol, 2012, 30: 285-289.Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol, 2012, 30: 285-289.Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol, 1999, 162: 74-76.Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol, 1999, 162: 74-76.Adiyat KT, Katkoori D, Soloway CT, De los Santos R, Manoharan M, Soloway MS. ‘Complete transurethral resection of bladder tumor’: are the guidelines being followed? Urology, 2010, 75: 365-367.Adiyat KT, Katkoori D, Soloway CT, De los Santos R, Manoharan M, Soloway MS. ‘Complete transurethral resection of bladder tumor’: are the guidelines being followed? Urology, 2010, 75: 365-367.Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol, 2012, 188: 361-368.Liu JJ, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol, 2012, 188: 361-368.Yang LP. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. Mol Diagn Ther, 2014, 18: 105-116.Yang LP. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer. Mol Diagn Ther, 2014, 18: 105-116.Witjes JA, Redorta JP, Jacqmin D et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol, 2010, 57: 607-614.Witjes JA, Redorta JP, Jacqmin D et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol, 2010, 57: 607-614.Witjes JA, Babjuk M, Gontero P et al. Clinical and cost effectiveness of hexaminolevulinateguided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol, 2014, 66: 863-871.Witjes JA, Babjuk M, Gontero P et al. Clinical and cost effectiveness of hexaminolevulinateguided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol, 2014, 66: 863-871.Yuan H, Qiu J, Liu L et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection i‘n patients with non-muscle invasive bladder cancer: a meta- analysis of randomized controlled trials. PLoS One. 2013, 8: e74142.Yuan H, Qiu J, Liu L et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection i‘n patients with non-muscle invasive bladder cancer: a meta- analysis of randomized controlled trials. PLoS One. 2013, 8: e74142.Burger M, Grossman HB, Droller M et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol, 2013, 64: 846-854.Burger M, Grossman HB, Droller M et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol, 2013, 64: 846-854.Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol, 2013, 64: 639-653.Babjuk M, Burger M, Zigeuner R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol, 2013, 64: 639-653.Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol, 2013, 63: 4-15.Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol, 2013, 63: 4-15.Stenzl A, Jocham D, Jichlinski P et al. Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A, 2008, 47: 982-987.Stenzl A, Jocham D, Jichlinski P et al. Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology. Urologe A, 2008, 47: 982-987.Bunce C, Ayres BE, Griffiths TR et al. The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. BJU Int, 2010, 105(Suppl 2): 2-7.Bunce C, Ayres BE, Griffiths TR et al. The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. BJU Int, 2010, 105(Suppl 2): 2-7.Malmstrom PU, Grabe M, Haug ES et al. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. Scand J Urol Nephrol, 2012, 46: 108-116.Malmstrom PU, Grabe M, Haug ES et al. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. Scand J Urol Nephrol, 2012, 46: 108-116.Giannarini G, Birkhauser FD, Recker F, Thalmann GN, Studer UE. Bacillus Calmette- Guerin failure in patients with non-muscleinvasive urothelial carcinoma of the bladder may be due to the urologist’s failure to detect urothelial carcinoma of the upper urinary tract and urethra. Eur Urol, 2014, 65: 825-831.Giannarini G, Birkhauser FD, Recker F, Thalmann GN, Studer UE. Bacillus Calmette- Guerin failure in patients with non-muscleinvasive urothelial carcinoma of the bladder may be due to the urologist’s failure to detect urothelial carcinoma of the upper urinary tract and urethra. Eur Urol, 2014, 65: 825-831.Burger M, Petschl S, Volkmer BG. Calculating the price of a new diagnostic or therapeutic option. Example of transurethral resection of bladder tumors using photodynamic diagnostics with hexaminolevulinic acid. Urologe A, 2008, 47: 1239-1244.Burger M, Petschl S, Volkmer BG. Calculating the price of a new diagnostic or therapeutic option. Example of transurethral resection of bladder tumors using photodynamic diagnostics with hexaminolevulinic acid. Urologe A, 2008, 47: 1239-1244.Dindyal S, Nitkunan T, Bunce CJ. The economic benefit of photodynamic diagnosis in nonmuscle invasive bladder cancer. Photodiagnosis Photodyn Ther, 2008, 5: 153-158.Dindyal S, Nitkunan T, Bunce CJ. The economic benefit of photodynamic diagnosis in nonmuscle invasive bladder cancer. Photodiagnosis Photodyn Ther, 2008, 5: 153-158.Malmstrom PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol, 2009, 43: 192-198.Malmstrom PU, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol, 2009, 43: 192-198.Otto W, Burger M, Fritsche HM et al. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clin Med Oncol, 2009, 3: 53-58.Otto W, Burger M, Fritsche HM et al. Photodynamic diagnosis for superficial bladder cancer: do all risk-groups profit equally from oncological and economic long-term results? Clin Med Oncol, 2009, 3: 53-58.Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int, 2012, 110: 680-687.Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int, 2012, 110: 680-687.Bryan RT, Billingham LJ, Wallace DM. Narrowband imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int, 2008, 101: 702-705.Bryan RT, Billingham LJ, Wallace DM. Narrowband imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int, 2008, 101: 702-705.Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumorsresults of a prospective, randomized comparison to the standard approach. Urology, 2012, 79: 846-851.Geavlete B, Multescu R, Georgescu D, Stanescu F, Jecu M, Geavlete P. Narrow band imaging cystoscopy and bipolar plasma vaporization for large nonmuscle-invasive bladder tumorsresults of a prospective, randomized comparison to the standard approach. Urology, 2012, 79: 846-851.Naito S, van Rees Vellinga S, de la Rosette J. Global randomized narrow band imaging versus white light study in nonmuscle invasive bladder cancer: accession to the first milestone- enrollment of 600 patients. J Endourol, 2013, 27: 1-3.Naito S, van Rees Vellinga S, de la Rosette J. Global randomized narrow band imaging versus white light study in nonmuscle invasive bladder cancer: accession to the first milestone- enrollment of 600 patients. J Endourol, 2013, 27: 1-3.Goh AC, Tresser NJ, Shen SS, Lerner SP. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology, 2008, 72: 133-137.Goh AC, Tresser NJ, Shen SS, Lerner SP. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology, 2008, 72: 133-137.Karl A, Stepp H, Willmann E et al. Optical coherence tomography for bladder cancer – ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. Eur J Med Res, 2010, 15: 131-134.Karl A, Stepp H, Willmann E et al. Optical coherence tomography for bladder cancer – ready as a surrogate for optical biopsy? Results of a prospective mono-centre study. Eur J Med Res, 2010, 15: 131-134.Schmidbauer J, Remzi M, Klatte T et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol, 2009, 56: 914-919.Schmidbauer J, Remzi M, Klatte T et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol, 2009, 56: 914-919.Wu K, Liu JJ, Adams W et al. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology, 2011, 78: 225-231.Wu K, Liu JJ, Adams W et al. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology, 2011, 78: 225-231.Crow P, Uff JS, Farmer JA, Wright MP, Stone N. The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro. BJU Int, 2004, 93: 1232-1236.Crow P, Uff JS, Farmer JA, Wright MP, Stone N. The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro. BJU Int, 2004, 93: 1232-1236.Draga RO, Grimbergen MC, Vijverberg PL et al. In vivo bladder cancer diagnosis by high- volume Raman spectroscopy. Anal Chem, 2010, 82: 5993-5999.Draga RO, Grimbergen MC, Vijverberg PL et al. In vivo bladder cancer diagnosis by high- volume Raman spectroscopy. Anal Chem, 2010, 82: 5993-5999.Vendrell M, Maiti KK, Dhaliwal K, Chang YT. Surface-enhanced Raman scattering in cancer detection and imaging. Trends Biotechnol, 2013, 31: 249-257.Vendrell M, Maiti KK, Dhaliwal K, Chang YT. Surface-enhanced Raman scattering in cancer detection and imaging. Trends Biotechnol, 2013, 31: 249-257.Jain M, Robinson BD, Scherr DS et al. Multiphoton microscopy in the evaluation of human bladder biopsies. Arch Pathol Lab Med, 2012, 136: 517-526.Jain M, Robinson BD, Scherr DS et al. Multiphoton microscopy in the evaluation of human bladder biopsies. Arch Pathol Lab Med, 2012, 136: 517-526.Goldman RE, Bajo A, MacLachlan LS, Pickens R, Herrell SD, Simaan N. Design and performance evaluation of a minimally invasive telerobotic platform for transurethral surveillance and intervention. IEEE Trans Biomed Eng, 2013, 60: 918-925.Goldman RE, Bajo A, MacLachlan LS, Pickens R, Herrell SD, Simaan N. Design and performance evaluation of a minimally invasive telerobotic platform for transurethral surveillance and intervention. IEEE Trans Biomed Eng, 2013, 60: 918-925.Schäfauer C, Ettori D, Rouprêt M et al. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. J Urol, 2013, 190: 271-277.Schäfauer C, Ettori D, Rouprêt M et al. Detection of bladder urothelial carcinoma using in vivo noncontact, ultraviolet excited autofluorescence measurements converted into simple color coded images: a feasibility study. J Urol, 2013, 190: 271-277.Pan Y, Volkmer JP, Mach KE et al. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Sci Transl Med, 2014, 6: 260ra148.Pan Y, Volkmer JP, Mach KE et al. Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Sci Transl Med, 2014, 6: 260ra148.Медицинская лабораторная диагностика (программы и алгоритмы). Под ред. проф. А.И. Карпищенко. СПб. 2001, 544 с.Медицинская лабораторная диагностика (программы и алгоритмы). Под ред. проф. А.И. Карпищенко. СПб. 2001, 544 с.Патент РФ «Способ дифференциальной диагностики злокачественных новообразований и соматических незлокачественных заболеваний». №2232391 от 10.07.2004.Патент РФ «Способ дифференциальной диагностики злокачественных новообразований и соматических незлокачественных заболеваний». №2232391 от 10.07.2004.Панченков А.Н. Энтропия. Н. Новгород, 1999, 592 с.Панченков А.Н. Энтропия. Н. Новгород, 1999, 592 с.Панченков А.Н. Энтропия-2. Н. Новгород, 2002, 713 с.Панченков А.Н. Энтропия-2. Н. Новгород, 2002, 713 с.Шатохина С.Н., Шабалин В.Н. Диагностическое значение профильной дегидратации сыворотки крови: структурная форма информации. Журнал для врачей «Лаборатория», 1999, 4: 3-5.Шатохина С.Н., Шабалин В.Н. Диагностическое значение профильной дегидратации сыворотки крови: структурная форма информации. Журнал для врачей «Лаборатория», 1999, 4: 3-5.

The authors declare that there are no conflicts of interest present.